Core Viewpoint - BioAge Labs, Inc. is facing a class action securities lawsuit due to alleged securities fraud related to its initial public offering and subsequent discontinuation of a key product trial, which led to a significant drop in stock price [1][3]. Group 1: Lawsuit Details - The lawsuit aims to recover losses for investors who purchased BioAge stock linked to its IPO on September 26, 2024 [2]. - The complaint highlights that BioAge announced the discontinuation of the STRIDES Phase 2 trial for azelaprag on December 6, 2024, due to safety concerns, which was unexpected given the positive outlook presented during the IPO [3]. - Following the announcement, BioAge's stock price plummeted from $20.09 per share to $4.65 per share within a day [3]. Group 2: Next Steps for Investors - Investors who suffered losses during the relevant period have until March 10, 2025, to request appointment as lead plaintiff in the lawsuit [4]. - Participation in the lawsuit does not require any out-of-pocket costs for class members [4]. Group 3: Firm Background - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions for shareholders over the past 20 years [5]. - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years as a leading securities litigation firm in the United States [5].

Core Viewpoint - A lawsuit has been filed against BioAge Labs, Inc. and its senior executives for potential violations of federal securities laws related to its initial public offering and subsequent trial discontinuation [1][2]. Group 1: Lawsuit Details - The lawsuit is based on claims under Sections 11 and 15 of the Securities Act of 1933, representing investors who purchased stock during BioAge's IPO on September 26, 2024 [2]. - The case is currently pending in the U.S. District Court for the Northern District of California, titled Soto v. BioAge Labs, Inc., et al., No. 25-cv-196 [2]. Group 2: Company Overview - BioAge Labs, Inc. is a clinical-stage biopharmaceutical company focused on developing therapeutic products for metabolic diseases, particularly obesity [3]. - The company's lead product candidate, azelaprag, is designed to enhance weight loss as an orally available small-molecule agonist of the apelin receptor [3]. Group 3: Clinical Trial Information - BioAge's IPO documents highlighted the ongoing STRIDES Phase 2 trial of azelaprag in combination with GLP-1R agonists, with expectations for topline results in Q3 2025 [4]. - The company claimed collaboration with Eli Lilly and Company for the trial's design and execution, asserting no safety concerns at the time [4]. Group 4: Trial Discontinuation and Stock Impact - The STRIDES Phase 2 trial was discontinued due to safety concerns after subjects exhibited elevated liver enzyme levels, indicating potential organ damage [5]. - Following the announcement of the trial's discontinuation on December 6, 2024, BioAge's stock price plummeted over 76%, from $20.09 per share to $4.65 per share within three days [6].

Core Viewpoint - BioAge Labs, Inc. is facing a class action lawsuit following the discontinuation of its STRIDES Phase 2 trial for azelaprag due to safety concerns, which led to a significant drop in its stock price [2]. Group 1: Lawsuit Details - The lawsuit is on behalf of shareholders who purchased BioAge stock during the class period related to its IPO on September 26, 2024 [1]. - The complaint alleges that BioAge's announcement on December 6, 2024, regarding the discontinuation of the azelaprag trial was unexpected, as the company had previously promoted the drug's potential [2]. - Following the announcement, BioAge's stock price plummeted from $20.09 per share to $4.65 per share within a day [2]. Group 2: Shareholder Actions - Shareholders are encouraged to register for the class action by March 10, 2025, to potentially become lead plaintiffs [3]. - Registered shareholders will receive updates through a portfolio monitoring software regarding the case's progress [3]. Group 3: Law Firm Background - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit and fraud [4]. - The firm aims to ensure companies engage in responsible business practices and seeks recovery for investors affected by misleading statements [4].

NEW YORK, Feb. 23, 2025 /PRNewswire/ --Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of stock of BioAge Labs, Inc. (NASDAQ: BIOA) pursuant and/or traceable to the registration statement for BioAge's initial public offering conducted on September 26, 2024 (the "IPO"), of the important March 10, 2025 lead plaintiff deadline.So what: If you purchased BioAge stock you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrange ...

RADNOR, Pa., Feb. 22, 2025 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com)  informs investors that a securities class action lawsuit has been filed against BioAge Labs, Inc. ("BioAge") (NASDAQ: BIOA) on behalf of those who purchased stock pursuant and/or traceable to BioAge's registration statement for its initial public offering ("IPO") held on or about September 26, 2024 (the "Class Period"). The lead plaintiff deadline is March 10, 2025.CONTACT KESSLER TOPAZ MELTZER & CH ...

RADNOR, Pa., Feb. 20, 2025 (GLOBE NEWSWIRE) -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed in the United States District Court for the Northern District of California against BioAge Labs, Inc. (“BioAge”) (NASDAQ: BIOA) on behalf of those who purchased stock pursuant and/or traceable to BioAge's registration statement for its initial public offering (“IPO”) held on or about September 26, 2024 (the “Class Period”). T ...

RICHMOND, Calif., Feb. 20, 2025 (GLOBE NEWSWIRE) -- BioAge Labs (Nasdaq: BIOA) (“BioAge”, “the Company”), a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging, today announced that the Company will participate in one-on-one meetings at TD Cowen's 45th Annual Health Care Conference. TD Cowen's 45th Annual Health Care Conference is taking place on March 3–5, 2025, at the Boston Marriott Copley Place in Boston, MA. T ...

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against BioAge Labs, Inc. due to alleged violations of federal securities laws related to misleading information about its STRIDES Phase 2 clinical trial [2][4]. Group 1: Company Overview - BioAge Labs, Inc. (NASDAQ: BIOA) completed its initial public offering on September 27, 2024, selling 12.65 million shares at $18 per share, including an additional 1.65 million shares purchased by underwriters [4]. - The company faced significant stock price decline following the announcement on December 6, 2024, that it would discontinue the STRIDES Phase 2 study of its drug candidate azelaprag due to liver transaminitis observed in subjects [5][6]. Group 2: Legal Proceedings - A federal securities class action has been filed against BioAge, with a deadline of March 10, 2025, for investors to seek the role of lead plaintiff [2]. - The complaint alleges that BioAge and its executives provided false and misleading information regarding the safety of their investigational drug candidate [4]. Group 3: Investor Impact - Investors who suffered losses exceeding $75,000 in BioAge between September 26, 2024, and January 7, 2025, are encouraged to discuss their legal rights with Faruqi & Faruqi [1]. - The stock price of BioAge fell from $20.09 per share on December 6, 2024, to $4.65 per share by December 9, 2024, indicating a significant loss for investors [6].

Core Viewpoint - A lawsuit has been filed against BioAge Labs, Inc. and its senior executives for potential violations of federal securities laws related to its initial public offering [1][2]. Group 1: Company Overview - BioAge Labs, Inc. is a clinical-stage biopharmaceutical company focused on developing therapeutic products for metabolic diseases, particularly obesity [3]. - The company's lead product candidate, azelaprag, is designed to enhance weight loss as an orally available small-molecule agonist of the apelin receptor [3]. Group 2: Legal Allegations - The lawsuit claims violations under Sections 11 and 15 of the Securities Act of 1933, concerning investors who purchased stock during BioAge's IPO on September 26, 2024 [2]. - The complaint alleges that BioAge misrepresented the safety and efficacy of its STRIDES Phase 2 trial for azelaprag, which was conducted in collaboration with Eli Lilly and Company [4]. Group 3: Trial and Stock Impact - BioAge's STRIDES Phase 2 trial was discontinued due to safety concerns after subjects exhibited elevated liver enzyme levels, indicating potential organ damage [5]. - Following the announcement of the trial's discontinuation on December 6, 2024, BioAge's stock price plummeted over 76%, from $20.09 to $4.65 per share within three days [6].

NEW YORK, Feb. 20, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of BioAge Labs, Inc. (NASDAQ: BIOA).Shareholders who purchased shares of BIOA during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/bioage-labs-inc-loss-submission-form/?id=130521&from=4CLASS PERIOD: This lawsuit is on ...